Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading RNA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.46%73.760.9%$699.22m
AMGNAmgen Inc.
0.50%180.211.1%$562.99m
CELGCelgene Corporation
1.05%137.741.1%$511.41m
REGNRegeneron Pharmaceuticals, Inc.
-1.00%515.922.7%$478.88m
VRTXVertex Pharmaceuticals Incorporated
2.41%163.171.9%$401.70m
BIIBBiogen Inc.
0.53%282.921.2%$362.26m
ALXNAlexion Pharmaceuticals, Inc.
1.53%131.791.9%$271.34m
TSROTESARO, Inc.
2.29%131.9714.7%$172.59m
ILMNIllumina, Inc.
0.45%172.753.5%$161.08m
INCYIncyte Corporation
0.32%134.222.6%$151.82m
EXELExelixis, Inc.
0.89%27.236.5%$148.60m
CLVSClovis Oncology, Inc.
1.61%86.6418.0%$130.90m
BMRNBioMarin Pharmaceutical Inc.
1.76%89.284.4%$127.08m
KITEKite Pharma, Inc.
-0.67%109.1516.1%$120.98m
SRPTSarepta Therapeutics, Inc.
6.06%43.4119.8%$112.50m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.